SPY305.60+0.05 0.02%
DIA256.22+0.95 0.37%
IXIC9,488.11-63.94 -0.67%

Barclays Maintains Underweight on Eidos Therapeutics, Lowers Price Target to $34

Barclays maintains Eidos Therapeutics (NASDAQ:EIDX) with a Underweight and lowers the price target from $45 to $34.

Benzinga · 05/11/2020 15:36

Barclays maintains Eidos Therapeutics (NASDAQ:EIDX) with a Underweight and lowers the price target from $45 to $34.